Home › Compound Library › Adalimumab (Humira)

Adalimumab (Humira)

Biologicprescriptionsubcutaneous · inferred

Fully human IgG1 monoclonal antibody targeting TNF-alpha; approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis, and uveitis. Typical dose 40 mg SC every 2 weeks after loading. Exhibits biphasic clearance: fast target-mediated phase (t1/2 ~1 day at steady-state) and slow linear phase (t1/2 ~14 days). SC bioavailability ~64%. Anti-drug antibodies can accelerate clearance.

Projected serum levels — 40 mg, custom (shown daily)

Adalimumab (Humira)
Adalimumab (Humira) modeled serum levels, 40 mg custom (shown daily) over 106 days Population-based pharmacokinetic estimate. Steady state reached after approximately 43 days. 0 250 500 750 1k Day 0 Day 27 Day 53 Day 80 Day 106 Time on a regular schedule ≈ steady state · day 43
Adalimumab (Humira) modeled serum levels with a loading dose of 120 mg, then 40 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 250 500 750 1k Day 0 Day 27 Day 53 Day 80 Day 106 Time on a regular schedule

Maintenance schedule: 40 mg custom (shown daily) (subcutaneous).

Loading schedule: 120 mg on day 1, then 40 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~43 days: peak ≈ 780 mg, trough ≈ 779 mg body load. Population-based estimate over 106 days for a 40 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Biologic
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
14 days
Common dose
40 mg
Suggested maximum
80 mg/day
Reference dose range
20–80 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
40 mg sc — Cmax 4.7 mg/L at 131 h

Research behind this entry

  1. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate Weisman MH et al. · Clinical Therapeutics, 2003 DOI

    Foundational PK/efficacy study establishing adalimumab's ~14-day terminal half-life, SC bioavailability, and dose-response in RA.

  2. Pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and tolerability of adalimumab Nestorov I · Seminars in Arthritis and Rheumatism, 2005 DOI

    Population PK review quantifying biphasic disposition, interpatient variability, and impact of anti-drug antibodies on clearance.

2 published studies referenced in the app, each with a plain-language summary.